HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $4 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintains $4 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintains $4 price target.